For more information, please visit www.numatix.net, contact info@numatix.net or follow us on Twitter @numatixData.

Numerate is currently making Numatix available to a broad range of users in the life sciences. Future applications in other fields, such as finance, manufacturing and energy, can be envisioned.  For more information, please visit www.numatix.net or contact info@numatix.net or follow us on Twitter @numatixData.

Numerate’s Drug Design Platform Scales to 10,000+ Cores Using Spot Instances;
Large-Scale Data Analyses Enabled by Numatix, Numerate’s Distributed Framework

SAN BRUNO, CA – June 10, 2012 – Numerate, Inc., a technology platform company that is leveraging proprietary algorithms and the power of cloud computing to transform the drug design process, announced today that its drug discovery platform, based on its open-source distributed framework, Numatix, has been shown to reliably and cost-effectively scale to 10,000+ cores using spot instances on Amazon Web Services’ Elastic Cloud Compute (AWS EC2). The 10,000+ cores were used to screen virtual compounds against predictive assay models in one of the company’s commercial partnerships.

Numatix is a dataflow processing platform developed by Numerate that enables great scalability and flexibility in distributed computing with minimal operational overhead. Combining online processing with detailed dataflows, Numatix allows for the deep and interactive analyses of large data sets. At Numerate, Numatix is used for the computational assessment of billions of molecules in the search for new drugs and for the development of complex systems biology models of drug behavior in various animals and humans.

“This level of scalability is essential for Numerate due to growing demand for our drug design services in the pharmaceutical and biotechnology industry,” said Nigel Duffy, Ph.D., Chief Technology Officer. “This achievement demonstrates the power of the Numatix platform and its ability to tackle large-scale computational problems cost effectively. We designed Numatix from the ground up to be extremely robust to all types of failures, allowing us to take full advantage of spot instances and their cost savings.”

“We were able to scale up to 10,000 nodes in the US-East zone of EC2,” stated Brandon Allgood, Ph.D., Director of Computational Science. “And because the Numatix platform uses spot instances, the cost was only 2.7¢ per core-hour, or $270 per hour for a 10,000-core cluster – just one-third of the on-demand cost. Moreover, we were able to reach this scale while handling spot instance ephemeralness and maintaining a high level of security.”

Allgood added, “The limiting factor on this run was our cloud provider-independent security layer. On less sensitive types of workloads, we expect that Numatix should be able to scale well beyond 10,000 cores.”

Numerate Announces Integration with Google Compute Engine

SAN BRUNO, CA – June 28, 2012 – Numerate, Inc., a technology platform company that uses proprietary algorithms and the power of cloud computing to transform the drug design process, today announced integration of its platform with Google Compute Engine. Numerate collaborates with pharmaceutical and biotechnology partners to increase the speed and cost effectiveness of small molecule drug discovery for important diseases such as cancer, infectious disease and neurodegenerative diseases, including Parkinson’s and Alzheimer’s disease.

Numerate’s in silico drug design platform features a set of proprietary algorithms that use machine learning to provide predictive models for molecular properties with accuracies comparable to laboratory testing.  Used in conjunction with cloud computing, these algorithms enable Numerate scientists to search through spaces of billions of compounds to rapidly and efficiently identify those with the highest probability of activity against a specific target.

“The development of new medicines is greatly constrained by the complexities and serendipity of traditional drug discovery methods,” said Nigel Duffy, PhD., Chief Technology Officer at Numerate. “We have built a new computational process to remove this bottleneck by assuming a world with unconstrained access to computational resources. Capabilities like Google Compute Engine make that assumption a reality, allowing us to meet the needs of our growing list of pharmaceutical collaborators.”

“Google Compute Engine is a flexible and easy-to-use platform offering a clean, simple API, a powerful security model, and the rapid provisioning of computational resources,” said Brandon Allgood, PhD., Director of Computational Sciences at Numerate. “Rapid provisioning is critical for us as we elastically scale to thousands of cores in response to our partners’ needs. Google Compute Engine excels in this regard. In fact, with a small amount of effort, we adapted our platform to Google Compute Engine and have already scaled to more than 10,000 cores.”

Numerate, whose drug design system is built on Numatix, an elastically scalable dataflow processing platform for cloud computing, is one of several Google Compute Engine partners.  “To help customers get the most out of our cloud platform products,” explained Eric Morse, Head of Sales and Business Development for Google’s cloud platform, “we work closely with technology companies that provide powerful complementary solutions integrated with our platform.”

For more information on Numerate’s drug design system, please visit www.numatix.net, and to learn more about the Google Compute Engine, go to http://cloud.google.com/compute

About Numerate

Numerate is a privately held biotechnology company pioneering new computational methods for making the drug design process more data-driven, efficient and predictable. Numerate’s in silico drug design platform combines proprietary algorithms and cloud computing with traditional medicinal chemistry approaches to address, in parallel, the factors that determine the success and failure of a drug candidate. Numerate applies this proprietary platform to design and develop small molecule therapeutics in collaboration with a variety of partners in the pharmaceutical, biotechnology, and academic fields.  For more information, please visit www.numerate.com (corporate site) and www.numerati.com (technical site) or follow Numatix on Twitter: @numatixData.

Numerate Forms Drug Discovery Collaboration with Merck to Utilize Numerate’s In Silico Drug Design Technology; Research to Focus on Cardiovascular Disease Target

SAN BRUNO, CA – March 14, 2012 – Numerate, Inc., a technology platform company that is leveraging proprietary algorithms and the power of cloud computing to transform the drug design process, announced today that it has entered into a research collaboration with Merck, through a subsidiary. The collaboration will utilize Numerate’s proprietary in silico drug design technology to generate novel small molecule drug leads for an undisclosed cardiovascular disease target.

“We are pleased to add Merck, a recognized leader in drug discovery innovation, to our growing number of pharmaceutical collaborators,” stated Numerate chief executive officer Guido Lanza.  “This collaboration is focused on increasing the speed, cost-efficiency and likelihood of generating new small molecule drug leads through the use of our large-scale computational drug design methods.”

Numerate’s drug design platform features a set of proprietary algorithms that provide predictive models for molecular properties with accuracies comparable to laboratory testing.  Used in conjunction with cloud computing, these algorithms enable Numerate scientists to search through spaces of billions of compounds to rapidly and efficiently identify those with the highest probability of activity against a specific target.

Numerate and Boehringer Ingelheim (Canada) Form Research Collaboration Based on In Silico Drug Design Technology; Drug Discovery Research to Focus on Infectious Disease Target

SAN BRUNO, CA – December 6, 2011 – Numerate, Inc., a technology platform company that is leveraging the power of cloud computing and novel computational methods to transform the drug design process, announced today that it has entered into a research collaboration with Boehringer Ingelheim (Canada) Ltd. The collaboration will utilize Numerate’s proprietary in silico drug design technology to generate novel small molecule drug leads for an undisclosed infectious disease target.

“Using our large-scale computational drug design methods, we expect to greatly reduce the time and cost of delivering new lead-stage, small molecule drug candidates in this important program for Boehringer Ingelheim,” stated Numerate chief executive officer Guido Lanza. “This collaboration is the latest in our growing number of partnerships with pharmaceutical companies that are looking to Numerate’s comprehensive in silico drug design technology to help them increase their success rate in generating novel, patentable small molecule leads.”

Numerate’s drug design platform features a set of proprietary algorithms that provide predictive models for molecular properties with accuracies comparable to laboratory testing.  Used in conjunction with cloud computing, these algorithms enable Numerate scientists to search through spaces of billions of compounds to rapidly and efficiently identify those with the highest probability of activity against a specific target.

Full References:

“Acylideneoxoindoles:  A new class of reversible inhibitors of human transglutaminase 2.“  C. Klöck, X. Jin, K. Choi, C. Khosla, P.B. Madrid, A. Spencer, B.C. Raimundo, P. Boardman, G. Lanza and J.H. Griffin. Bioorg. Med. Chem. Lett. 2011, 21, 2692-2696.

“Identification of new inhibitors of protein kinase R guided by statistical modeling.“  R. Bryk, K. Wu, B.C. Raimundo, P.E. Boardman, P. Chao, G.L. Conn, E. Anderson, J.L. Cole, N.P. Duffy, C. Nathan and J.H. Griffin. Bioorg. Med. Chem. Lett. 2011, 21, 4108-4114.

Numerate, Inc., a technology platform company that is leveraging proprietary algorithms and the power of cloud computing to transform the drug design process, announced today that David Jobes, Ph.D., has joined the company as senior vice president of business and corporate development.

Dr. Jobes brings over 10 years of biopharmaceutical industry experience to Numerate from such diverse areas as diagnostics, vaccines, and small molecule therapeutics. Prior to joining Numerate, he successfully headed his own consulting firm focused on assisting clients with transactional work and business development strategies. Previously, he was co-founder and vice president of business development at Presidio Pharmaceuticals, a small molecule antiviral company. Dr. Jobes also served in various research and leadership roles at VaxGen, Applied Biosystems, and the National Institutes of Health (NIH).

“We are very pleased to welcome Dave to the executive management team at Numerate,” stated Guido Lanza, chief executive officer of Numerate. “His depth of experience in the biotech industry and record of deal making is a major benefit as we continue to expand our corporate partnerships beyond the big pharma relationships we currently have in place.”

“This is an exciting time to be joining Numerate,” commented Dr. Jobes. “It is with technologies like Numerate’s that we will finally begin to regain control of the spiraling time, money and resource costs currently required for generating a small molecule lead. Numerate’s proprietary strategy of combining medicinal chemistry, statistics and computer science, driven by state-of-the-art cloud computing, should help revolutionize the way companies design and discover novel, patentable small molecules.”